{'fraction_non_alphanumeric': 0.026812313803376366, 'fraction_numerical': 0.015888778550148957, 'mean_word_length': 6.048951048951049, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Letter: "High-dose" metronidazole: a preliminary pharmacological study prior to its investigational use in clinical radiotherapy trials.

Chemicals which selectively radiosensitize hypoxic mammalian cells have been considered as adjuvants in the radiotherapy of human tumours (Adams, 1973). The screening of various nitroheterocyclic drugs indicated numerous structures which are active as sensitizers in mammalian cells in vitro (Chapman, Reuvers and Borsa, 1973). The discovery that some drugs with current clinical usage were excellent radiosensitizers of hypoxic mammalian cells (Reuvers, Chapman and Borsa, 1972; Chapman et al., 1972), generated some optimism as regards an early clinical trial. A successful application of such drugs in the radiotherapy of human tumours would depend upon favourable pharmacological properties. In the selection of metronidazole for this study, radiosensitizing effectiveness at low drug concentration was sacrificed in favour of acceptable pharmacological properties.